EndoPredict, a multigene expression profiling test that predicts the likelihood of distant recurrence in patients with HR-positive, HER2-negative BC treated with adjuvant ET,[16] has been proven to be highly prognostic in node-negative or node-positive disease for early and late recurrence,[19–21] and also predicts benefit from adjuvant CT.[22] Additionally, it has been shown to be an independent prognostic parameter both in premenopausal and postmenopausal women treated with CT.[23]. Here, ERBB2 is linked to breast cancer.